Alkermes (ALKS)
(Delayed Data from NSDQ)
$26.55 USD
+0.06 (0.23%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $26.54 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Fundamental Charts
About Market Cap
As of the previous market close, Alkermes plc has a market cap of $4.37B, which represents its share price of $26.49 multiplied by its outstanding shares number of 165.08M. As a mid-cap company, ALKS's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ALKS 26.55 +0.06(0.23%)
Will ALKS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALKS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALKS
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
ALKS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
Other News for ALKS
Alkermes (ALKS) Target Price Raised by RBC Capital | ALKS Stock News
Alkermes: A More Than Solid Quarter
Decoding Alkermes PLC (ALKS): A Strategic SWOT Insight
Alkermes PLC (ALKS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Q2 2025 Alkermes Plc Earnings Call Transcript